Atmo Biosciences Company

Atmo is a clinical stage digital health business focussed on empowering researchers, clinicians and patients with objective real-time insights into gut health and microbiome function. Atmo addresses the unmet clinical need to monitor microbiome function, allowing better diagnosis and management of personalised therapies for gastrointestinal disorders, resulting in improved gut health and wellness. The company is underpinned by a world-first ingestible gas-sensing capsule + cloud platform, which continuously measures clinically important gaseous biomarkers during transit through the gut and transmits the data wirelessly to the cloud for aggregation and analysis, to determine gut health or dysfunction, resulting in earlier relief of symptoms through personalised therapeutic approaches.

Founded Date: 25.10.2018
Last Funding Type: Seed
Headquarters: Asia-Pacific (APAC), Australasia
Technology: Clinical Data Management Platforms, diagnostics
Employee Number: 43840
Industry: Clinical Data Management, Health Care, Health Diagnostics, Personal Health
Last Funding Date: 2019-11-30
Funding Status: Seed
Investor Type: For Profit
Total Funding: $3.5M